companies / ambrosiabiosciences-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-02 json
| total_raised | 150,000,000150.0M | ○ |
|---|---|---|
| founded | 2022 | |
| hq | Boulder CO | |
| industry | unknown | |
| stage | series-b+ |
Drug discovery company developing oral small-molecule therapies for obesity and metabolic disease via GPCR targets. Targets pharma partners and metabolic-disease patients underserved by peptide GLP-1s. Differentiates with structure-based discovery combining cryo-EM, biophysical assays, and AI molecular design.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2026-04-01 | series-b | 100,000,000100.0M | null | ○ |
Cloudflare, WordPress 6.9.4, jQuery Migrate 3.4.1, Popper, Cloudflare Bot Management, Vercel Speed Insights, web-vitals, PHP, MySQL, jquery 3.7.1, bootstrap 5.3.2
| fact | status | src |
|---|---|---|
| Series B, $100.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |